Cover Image
市場調查報告書

Cyramza(大腸癌症):市場預測與分析

Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 321689
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
Cyramza(大腸癌症):市場預測與分析 Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023
出版日期: 2014年11月28日 內容資訊: 英文 72 Pages
簡介

Eli Lilly所開發的Cyramza(ramucirumab)是抗VEGFR人IgG1單株抗體的血管新生抑制劑,目前是臨床實驗第ⅢPHASE的轉移性大腸癌治療藥。此外同時也在進行針對乳癌、胃癌、肝細胞癌(HCC)、非小細胞癌(NSCLC)等其他癌症上的治療研究。Cyramza的第ⅢPHASE實驗是針對在進行Avastin與FOLFOX併用療法到一半或之後發病的轉移性大腸癌所用的第二選擇療法之活用法研究。同時該公司更以1050名轉移性大腸癌患者為對象,進行在Cyramza與FOLFIRI併用的情況與單獨使用FOLFIRI的情況比較用的隨機化、雙重盲檢、安慰劑之比較實驗。

本報告提供大腸癌症的治療藥之一──Cyramza(ramucirumab)的全球市場相關分析,提供大腸癌症概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Cyramza的商品資訊(特色·功效·安全性等),調查著全球主要國家的市場販售額預測(今後10年份)等。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定出版的相關調查報告

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 臨床階段
  • 症狀

第4章 疾病管理

  • 診斷·治療概要
    • 篩檢及診斷
    • 治療的指南及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 未滿足需求及機會

  • 概要
  • 具有大幅改善轉移性患者存活率可能性的治療方法
    • 未滿足需求
    • 差距分析
    • 機會
  • 針對KRAS·BRAF突然變異陽性的患者之標靶治療
  • 是針對高風險且可切除之轉移部位,有效果的新佐劑/佐劑治療方法
  • 針對化療抗性患者之後期治療

第7章 開發平台評估

  • 概要
  • 臨床實驗階段的有潛力的藥劑

第8章 Cyramza(ramucirumab)

  • 概要
  • 有效性
  • 安全性
  • 給藥及製劑
  • 在臨床方面·商業方面的潛在的定位
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC476DFR

GlobalData has released its new PharmaPoint Drug Evaluation report, "Cyramza (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Eli Lilly's Cyramza (ramucirumab) is an anti-VEGFR human IgG1 monoclonal antibody angiogenesis inhibitor being investigated by Eli Lilly in Phase III clinical trials for the treatment of metastatic CRC, and has been investigated in a host of other oncology indications, including breast cancer, gastric cancer, HCC, and NSCLC. A Phase III study (RAISE) is investigating ramucirumab as a treatment for second-line metastatic CRC patients who have progressed during, or following, combination treatment with Avastin and FOLFOX. The randomized, double-blind, placebo-controlled study is evaluating ramucirumab in combination with FOLFIRI against FOLFIRI alone in 1,050 metastatic CRC patients.

Scope

  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cyramza including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cyramza for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Cyramza performance
  • Obtain sales forecast for Cyramza from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Screening and Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Cyramza (Ramucirumab)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. SWOT Analysis
  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Colorectal Cancer Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Average Body Weight and Surface Area Across the 8MM
    • 9.4.5. Generic Erosion
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Treatment Guidelines for CRC
  • Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 6: Leading Treatments for CRC, 2014
  • Table 7: Unmet Need and Opportunity in CRC
  • Table 8: Product Profile - Cyramza
  • Table 9: Cyramza SWOT Analysis, 2014
  • Table 10: Global Sales Forecasts ($m) for Cyramza, 2013-2023
  • Table 11: Average Body Weight and Surface Area Across the 8MM
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: CRC - Phase III Pipeline
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
  • Figure 3: Clinical and Commercial Positioning of Cyramza
Back to Top